Inhibikase Therapeutics (IKT) Financials: Revenue & Earnings
IKT$1.58+0.01 +0.67%
$220.54M
Market Cap
-3.35
P/E
6.52
Forward P/E
68
Score
Inhibikase Therapeutics (IKT) Financials: Revenue & Earnings
IKT price $1.58 +0.01 +0.67%
- Ticker
- IKT
- Price
- $1.58
- Change
- +0.01 +0.67%
- Market cap ?
- $220.54M
- P/E ?
- -3.35
- Forward P/E ?
- 6.52
- Dividend yield ?
- 0.00%
- Beta ?
- 0.90
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 68
- Value
- 57
- Quality
- 48
- Growth
- 100
Stocklytics score rationale: value 57, quality 48, growth 100.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 967386 | 2060937 | 4040955 | 1122740 | 698468 | 3100605 | 123440 | 260500 | 0 | 0 |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate…
Fair value
IKT fair value $5.24. Price $1.58. Price is 70% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 26.48K. Growth 3.13%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 9.24% (beta 0.9). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 139.54M. Net debt -139.22M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-13 | — | -0.11 | — | 187.50K |
| 2026-08-11 | -0.11 | -0.11 | — | — |
| 2026-05-12 | -0.10 | -0.10 | — | — |
| 2026-03-26 | -0.09 | -0.12 | — | — |
| 2025-11-14 | -0.13 | -0.13 | — | — |
| 2025-08-14 | -0.11 | -0.09 | — | — |
| 2025-05-14 | -0.15 | -0.11 | — | — |
| 2025-03-27 | 0.88 | -0.10 | — | — |
| 2024-11-14 | -0.65 | -0.38 | — | — |
| 2024-08-14 | -0.66 | -0.58 | — | — |
| 2024-05-15 | -0.73 | -0.79 | — | — |
| 2024-03-27 | -0.63 | -0.78 | 1 | — |
| 2023-11-14 | -0.86 | -1.12 | 79.57K | — |
| 2023-08-14 | -1.11 | -0.92 | 116.41K | — |
| 2023-05-16 | -0.96 | -0.15 | 64.52K | — |
| 2023-03-31 | -1.02 | -1.14 | 53.44K | — |
| 2022-11-14 | -1.08 | -0.18 | 7.29K | 200.00K |
| 2022-08-12 | -1.08 | -0.19 | 6.55K | 300.00K |
| 2022-05-16 | -1.08 | -0.17 | 46.03K | 300.00K |
| 2022-03-31 | -1.20 | -0.17 | 1.94K | 300.00K |
| 2021-11-15 | -1.08 | -0.14 | 328.46K | 300.00K |
| 2021-08-16 | -1.32 | -0.38 | 1.36M | 300.00K |
| 2021-05-17 | -1.56 | — | 1.41M | — |
| 2021-03-31 | -0.87 | — | 698.47K | — |
| 2020-09-30 | -0.49 | — | 37.68K | — |
| 2020-06-30 | -0.31 | — | 219.59K | — |
| 2020-03-31 | -0.40 | — | 270.79K | — |
| 2019-12-31 | -0.32 | — | 240.28K | — |
| 2019-09-30 | -0.89 | — | 124.43K | — |
| 2019-06-30 | -1.72 | — | 166.93K | — |
| 2019-03-31 | -1.27 | — | 591.10K | — |
| 2018-12-31 | -0.74 | — | 1.35M | — |
| 2018-03-31 | -0.10 | — | 691.20K | — |
| 2017-12-31 | 0.03 | — | 797.40K | — |
| 2017-03-31 | -0.14 | — | 247.38K | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Wasserman Scott M. | Buy | 310.00K | $1.65 | 509.95K |
| 2026-10-19 | Wasserman Scott M. | Other | 0 | — | — |
| 2026-07-30 | BERMAN DENNIS N | Buy | 21.85K | $1.26 | 27.54K |
| 2026-07-30 | BERMAN DENNIS N | Sell | 21.85K | $1.26 | 27.54K |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | Buy | 18.03M | $0.00 | 18.03K |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | Sell | 18.03M | $0.00 | 18.03K |
| 2026-07-10 | RA CAPITAL MANAGEMENT, L.P. | Other | 0 | — | — |
| 2026-06-26 | BERMAN DENNIS N | Buy | 155.00K | $1.91 | 296.05K |
| 2026-06-26 | Canner David | Buy | 155.00K | $1.91 | 296.05K |
| 2026-06-26 | Kush Arvind | Buy | 155.00K | $1.91 | 296.05K |
| 2026-06-26 | Bellini Roberto | Buy | 155.00K | $1.91 | 296.05K |
| 2026-06-26 | Aurentz Vincent | Buy | 155.00K | $1.91 | 296.05K |
| 2026-06-26 | Munshi Amit | Buy | 155.00K | $1.91 | 296.05K |
| 2026-02-21 | Aurentz Vincent | Sell | 255.30K | — | — |
| 2026-02-21 | Cabell Christopher | Sell | 338.28K | — | — |
| 2026-02-21 | Munshi Amit | Sell | 19.09K | — | — |
| 2026-01-05 | Iwicki Mark T | Buy | 4.98M | $2.01 | 10.02M |
| 2026-01-05 | Cabell Christopher | Buy | 900.12K | $2.01 | 1.81M |
| 2026-01-05 | McIntyre David | Buy | 986.32K | $2.01 | 1.98M |
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | Buy | 2.07M | $1.45 | 3.00M |
| 2025-06-30 | Aurentz Vincent | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-30 | Canner David | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-30 | Munshi Amit | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-30 | Kush Arvind | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-30 | BERMAN DENNIS N | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-30 | Bellini Roberto | Buy | 108.18K | $1.95 | 210.94K |
| 2025-06-06 | Sands Capital Life Sciences Pulse Fund II, L.P. | Other | 0 | — | — |
| 2025-04-14 | McIntyre David | Buy | 1.78M | $2.00 | 3.55M |
| 2025-04-14 | McIntyre David | Other | 0 | — | — |
| 2025-02-21 | Cabell Christopher | Other | 0 | — | — |
| 2025-02-21 | Aurentz Vincent | Other | 0 | — | — |
| 2025-02-21 | Munshi Amit | Buy | 57.27K | — | — |
| 2025-02-21 | Cabell Christopher | Buy | 1.10M | $2.97 | 3.27M |
| 2025-02-21 | Iwicki Mark T | Buy | 602.35K | $2.97 | 1.79M |
| 2025-02-21 | Aurentz Vincent | Buy | 134.43K | $2.97 | 399.25K |
| 2025-02-21 | Cabell Christopher | Buy | 1.10M | $2.23 | 2.45M |
| 2025-02-21 | Aurentz Vincent | Buy | 134.43K | $2.23 | 299.77K |
| 2025-02-21 | Iwicki Mark T | Buy | 602.35K | $2.23 | 1.34M |
| 2025-02-21 | Cabell Christopher | Other | 0 | — | — |
| 2025-02-21 | Aurentz Vincent | Other | 0 | — | — |
| 2025-02-17 | Iwicki Mark T | Buy | 1.79M | $2.35 | 4.22M |
| 2025-02-14 | Iwicki Mark T | Buy | 4.37M | $2.35 | 10.28M |
| 2025-02-14 | Iwicki Mark T | Other | 0 | — | — |
| 2025-02-14 | Kush Arvind | Buy | 116.58K | $2.35 | 273.97K |
| 2025-02-14 | Kush Arvind | Buy | 56.60K | $2.35 | 133.01K |
| 2025-02-14 | Bellini Roberto | Buy | 116.58K | $2.35 | 273.97K |
| 2025-02-14 | Bellini Roberto | Buy | 73.58K | $2.35 | 172.91K |
| 2025-02-14 | Freeman Roy Lester | Buy | 22.64K | $2.35 | 53.20K |
| 2025-02-14 | Munshi Amit | Buy | 116.58K | $2.35 | 273.97K |
| 2025-02-14 | Munshi Amit | Buy | 56.60K | $2.35 | 133.01K |
| 2025-02-14 | Canner David | Buy | 116.58K | $2.35 | 273.97K |
| 2025-02-14 | Canner David | Buy | 22.64K | $2.35 | 53.20K |
| 2025-02-14 | BERMAN DENNIS N | Buy | 39.62K | $2.35 | 93.11K |
| 2025-01-21 | Lees-Rolfe Garth | Buy | 90.00K | $1.26 | 113.40K |
| 2025-01-21 | Lees-Rolfe Garth | Buy | 5.83K | $1.26 | 7.35K |
| 2025-01-21 | Lees-Rolfe Garth | Sell | 90.00K | $2.16 | 194.40K |
| 2025-01-21 | Lees-Rolfe Garth | Sell | 5.83K | $3.79 | 22.11K |
| 2025-01-21 | Freeman Roy Lester | Buy | 30.00K | $1.26 | 37.80K |
| 2025-01-21 | Freeman Roy Lester | Buy | 21.85K | $1.26 | 27.54K |
| 2025-01-21 | Freeman Roy Lester | Buy | 6.67K | $1.26 | 8.40K |
| 2025-01-21 | Freeman Roy Lester | Buy | 3.78K | $1.26 | 4.76K |
| 2025-01-21 | Freeman Roy Lester | Buy | 1.14K | $1.26 | 1.43K |
| 2025-01-21 | Freeman Roy Lester | Sell | 6.67K | $3.61 | 24.07K |
| 2025-01-21 | Freeman Roy Lester | Sell | 21.85K | $33.43 | 730.58K |
| 2025-01-21 | Freeman Roy Lester | Sell | 1.14K | $60.00 | 68.28K |
| 2025-01-21 | Freeman Roy Lester | Sell | 3.78K | $17.52 | 66.23K |
| 2025-01-21 | Freeman Roy Lester | Sell | 6.67K | $4.86 | 32.40K |
| 2025-01-21 | Freeman Roy Lester | Sell | 30.00K | $1.54 | 46.20K |
| 2025-01-21 | Werner Milton H. | Buy | 45.00K | $1.26 | 56.70K |
| 2025-01-21 | Werner Milton H. | Buy | 35.00K | $1.26 | 44.10K |
| 2025-01-21 | BERMAN DENNIS N | Buy | 30.00K | $1.26 | 37.80K |
| 2025-01-21 | BERMAN DENNIS N | Buy | 21.85K | $1.26 | 27.54K |
| 2025-01-21 | Werner Milton H. | Buy | 20.83K | $1.26 | 26.25K |
| 2025-01-21 | Werner Milton H. | Buy | 16.67K | $1.26 | 21.00K |
| 2025-01-21 | BERMAN DENNIS N | Buy | 6.67K | $1.26 | 8.40K |
| 2025-01-21 | BERMAN DENNIS N | Buy | 3.78K | $1.26 | 4.76K |
| 2025-01-21 | Werner Milton H. | Buy | 3.64K | $1.26 | 4.59K |
| 2025-01-21 | BERMAN DENNIS N | Buy | 1.14K | $1.26 | 1.43K |
| 2025-01-21 | Werner Milton H. | Sell | 3.64K | $33.43 | 121.79K |
| 2025-01-21 | Werner Milton H. | Sell | 3.64K | $13.86 | 50.49K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 21.85K | $33.43 | 730.58K |
| 2025-01-21 | Werner Milton H. | Sell | 35.00K | $4.44 | 155.40K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 6.67K | $4.86 | 32.40K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 6.67K | $3.61 | 24.07K |
| 2025-01-21 | Werner Milton H. | Sell | 45.00K | $2.16 | 97.20K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 3.78K | $17.52 | 66.23K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 30.00K | $1.54 | 46.20K |
| 2025-01-21 | BERMAN DENNIS N | Sell | 1.14K | $60.00 | 68.28K |
| 2025-01-21 | Werner Milton H. | Sell | 20.83K | $6.42 | 133.75K |
| 2025-01-21 | Werner Milton H. | Sell | 16.67K | $60.00 | 1.00M |
| 2025-01-21 | Werner Milton H. | Sell | 3.64K | $28.76 | 104.77K |
| 2025-01-03 | Werner Milton H. | Buy | 5.32M | $1.26 | 6.70M |
| 2025-01-03 | Werner Milton H. | Buy | 4.06M | $1.58 | 6.41M |
| 2025-01-03 | Werner Milton H. | Buy | 2.21M | $1.45 | 3.20M |
| 2025-01-03 | Lees-Rolfe Garth | Buy | 470.86K | $1.26 | 593.28K |
| 2025-01-03 | Lees-Rolfe Garth | Buy | 432.85K | $1.58 | 683.91K |
| 2025-01-03 | Lees-Rolfe Garth | Buy | 235.38K | $1.45 | 341.31K |
| 2025-01-03 | Freeman Roy Lester | Buy | 344.45K | $1.26 | 434.01K |
| 2025-01-03 | Freeman Roy Lester | Buy | 316.65K | $1.58 | 500.30K |
| 2025-01-03 | Freeman Roy Lester | Buy | 172.19K | $1.45 | 249.68K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 107, holders +3 vs prior quarter. Ownership 67.67%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| SANDS CAPITAL ALTERNATIVES, LLC | 13.02M | 0 | 0.00% | 26.43M |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 10.88M | 0 | 0.00% | 22.08M |
| TRAILS EDGE CAPITAL PARTNERS, LP | 9.05M | 993.97K | +12.34% | 18.37M |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 8.62M | 0 | 0.00% | 17.51M |
| BLACKROCK, INC. | 7.77M | 1.46M | +23.24% | 15.77M |
| ADAR1 CAPITAL MANAGEMENT, LLC | 7.39M | 780.63K | +11.82% | 15.00M |
| BLACKSTONE INC. | 5.94M | 0 | 0.00% | 12.05M |
| SIREN, L.L.C. | 5.85M | 0 | 0.00% | 11.88M |
| COMMODORE CAPITAL LP | 5.40M | 0 | 0.00% | 10.96M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.94M | 484.69K | +10.89% | 10.02M |
| MILLENNIUM MANAGEMENT LLC | 4.03M | 1.10M | +37.57% | 8.18M |
| SATURN V CAPITAL MANAGEMENT LP | 3.87M | 5.61K | +0.15% | 7.85M |
| KALEHUA CAPITAL MANAGEMENT LLC | 3.82M | 0 | 0.00% | 7.76M |
| SPRUCE STREET CAPITAL LP | 3.58M | 0 | 0.00% | 7.27M |
| SQUADRON CAPITAL MANAGEMENT LLC | 3.00M | -500.00K | -14.29% | 6.09M |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 2.70M | 0 | 0.00% | 5.48M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.61M | 436.94K | +20.13% | 5.29M |
| STATE STREET CORP | 1.91M | 223.28K | +13.24% | 3.88M |
| SUMMITTX CAPITAL, L.P. | 1.78M | 255.73K | +16.77% | 3.61M |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.35M | 0 | 0.00% | 2.74M |
| NORTHERN TRUST CORP | 878.59K | 159.78K | +22.23% | 1.78M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 809.49K | 191.76K | +31.04% | 1.64M |
| TWO SIGMA INVESTMENTS, LP | 806.26K | -41.35K | -4.88% | 1.64M |
| SPHERA FUNDS MANAGEMENT LTD. | 649.31K | 649.31K | New | 1.32M |
| VANGUARD FIDUCIARY TRUST CO | 607.26K | 40.26K | +7.10% | 1.23M |
Earnings and financials
Inhibikase Therapeutics, Inc. (IKT) trades at $1.58, with a market cap of $220.54M and a trailing P/E of -3.35. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 967386 | 2060937 | 4040955 | 1122740 | 698468 | 3100605 | 123440 | 260500 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn